The prepared list will become the basis for further work on the reimbursement of drug technologies included in the list.
The creation of a list of highly innovative drug technologies (TLIs) is a systemic solution aimed at supporting efforts to improve health and quality of life.
The drugs evaluated were those for which the decision on marketing authorization in the central procedure in the European Union (EU) was issued from January 1, 2023 to December 31, 2023, for which marketing authorization decisions were published by 31.12.2023). According to a compilation by the European Medicines Agency (EMA), 60 medicinal products were authorized in the EU during the aforementioned period.
Drugs that received marketing authorization...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
